Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00580216 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3,773
- Enrollment target
NCT00580216 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 3,773 participants.
The verdict
NCT00580216, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3,773 participants
- Enrollment target
Study Summary
The objective is to evaluate whether once weekly subcutaneous (SC) injection of idrabiotaparinux sodium (biotinylated idraparinux) is at least as efficient to prevent clots in brain and in the other organs than oral international normalized ratio (INR) adjusted-dose warfarin in patients with atrial fibrillation (AF).
Interventions
- DRUG Warfarin
- DRUG Idrabiotaparinux sodium
- DRUG Avidin
- DRUG Placebo (for warfarin)
- DRUG Placebo (for idrabiotaparinux)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,773 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00580216
The ClinicalTrials.gov registry entry for NCT00580216 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 3,773 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Warfarin is the first listed.
NCT00580216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00580216 about?
NCT00580216 is a clinical study titled "Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation". The objective is to evaluate whether once weekly subcutaneous (SC) injection of idrabiotaparinux sodium (biotinylated idraparinux) is at least as efficient to prevent clots in brain and in the other organs than oral international normalized ratio (INR) adjusted-dose warfarin in patients with atrial ...
What is the current status of trial NCT00580216?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3,773 participants. The study started on 2007-12. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00580216?
The interventions under investigation include: Warfarin (DRUG), Idrabiotaparinux sodium (DRUG), Avidin (DRUG), Placebo (for warfarin) (DRUG), Placebo (for idrabiotaparinux) (DRUG).
Who is sponsoring clinical trial NCT00580216?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.